Vitamin D3 differentially regulates parathyroid hormone/parathyroid hormone-related peptide receptor expression in bone and cartilage

Norio Amizuka, Mei Yee Kwan, David Goltzman, Hidehiro Ozawa, and John H. White

1Department of Oral Anatomy, Niigata University School of Dentistry, Niigata 951-8514, Japan
2Departments of Physiology and Medicine, McGill University, Montreal, Quebec H3G 1Y6, Canada
3Calcium Research Laboratory, Royal Victoria Hospital and McGill University, Montreal, Quebec H3A 1A1, Canada

Address correspondence to: Norio Amizuka, 1st Department of Oral Anatomy, Niigata University School of Dentistry, 5274, 2-Bancho, Gakkoucho-Dori, Niigata 951-8514, Japan. Phone: 81-25-227-2814; Fax: 81-25-227-0804; E-mail: amizuka@dent.niigata-u.ac.jp

Received for publication March 4, 1998, and accepted in revised form December 18, 1998.

Introduction
Calcium homeostasis is largely controlled by the action of parathyroid hormone (PTH) and the secosteriod 1α,25-dihydroxyvitamin D3 (D3). PTH is secreted by the parathyroid gland in response to a reduction in extracellular fluid calcium and mobilizes calcium from bone, stimulating its reabsorption in the kidney (1, 2). D3 also stimulates bone resorption and calcium release from bone, but not in chondrocytes, under conditions where it enhanced bone resorption. Treatment of the osteoblastic cell line MC3T3-E1 with D3 in vitro reduced expression of both P2-specific transcripts and PTH receptor protein. This effect was not blocked by cycloheximide, indicating that D3 inhibits PTH expression by downregulating transcription of the P2 promoter. A similar inhibitory effect of D3 was not observed in the chondrocytic cell line CFK2. Gene-transfer experiments showed that P2, but not P1, is active in both MC3T3-E1 and CFK2 cells, and that D3 specifically inhibited P2 promoter activity in MC3T3-E1, but not in CFK2 cells. Inhibition of P2 activity by D3 required promoter sequences lying more than 1.6 kb upstream of the P2 transcription start site. Thus, the P2 promoter controls PTH receptor gene expression in both osteoblasts and chondrocytes. D3 downregulates PTH receptor gene transcription in a cell-specific manner by inhibiting P2 promoter activity in osteoblasts, but not in chondrocytes.


Transcription of the mouse parathyroid hormone (PTH)/PTH-related peptide (PTHR) receptor (PTHR) gene is controlled by promoters P1 and P2. We performed transcript-specific in situ hybridization and found that P2 is the predominant promoter controlling PTH receptor gene expression in bone and cartilage. Treatment with 1α,25-dihydroxyvitamin D3 (D3) in vivo specifically downregulated P2-specific transcripts in osteoblasts, but not in chondrocytes, under conditions where it enhanced bone resorption. Treatment of the osteoblastic cell line MC3T3-E1 with D3 in vitro reduced expression of both P2-specific transcripts and PTH receptor protein. This effect was not blocked by cycloheximide, indicating that D3 inhibits PTH expression by downregulating transcription of the P2 promoter. A similar inhibitory effect of D3 was not observed in the chondrocytic cell line CFK2. Gene-transfer experiments showed that P2, but not P1, is active in both MC3T3-E1 and CFK2 cells, and that D3 specifically inhibited P2 promoter activity in MC3T3-E1, but not in CFK2 cells. Inhibition of P2 activity by D3 required promoter sequences lying more than 1.6 kb upstream of the P2 transcription start site. Thus, the P2 promoter controls PTH receptor gene expression in both osteoblasts and chondrocytes. D3 downregulates PTH receptor gene transcription in a cell-specific manner by inhibiting P2 promoter activity in osteoblasts, but not in chondrocytes.
In this study, we have examined the tissue distribution and promoter specificity of PTHR gene expression in bone and cartilage. We find that P2 is the predominant PTHR promoter in both bone and cartilage and that expression of the PTHR gene is inhibited by D3 in bone, but not in cartilage, through downregulation of P2 activity. Given that the D3 receptor (VDR) is expressed in both osteoblasts and chondrocytes, our results suggest that the inhibitory effect of D3 on PTHR gene expression requires tissue-specific transcriptional repressors expressed in bone, but not in cartilage.

Methods
Administration of D3 to mice and treatment of MC3T3-E1 cells in culture. D3 (Chugai Pharmaceutical Co., Tokyo, Japan) was injected peritoneally into 5-week-old male ddY mice (Nihon SLC Co., Hamamatsu, Japan) at a concentration of 10^{-7} M D3 per animal three times a day for 2 days. Mice were then perfused with 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4) through the left ventricle, and tibiae were immersed in the same fixative for 7–9 h at 4°C. In control experiments, diluent was injected instead of D3. The murine osteoblastic cell line MC3T3-E1 (Riken Cell Bank, Ibaraki, Japan) were cultured with α-MEM (Flow Laboratories, Irvine, Scotland) containing 10% FCS to 70% confluence. They were then cultured with α-MEM containing 10% FCS and 10^{-7} M D3, in the absence of phenol red, for 24 h. In control experiments, MC3T3-E1 cells were cultured with α-MEM containing 10% FCS without D3 and phenol red.

Reverse transcription-PCR amplification of PTHR and glyceraldehyde-3-phosphate dehydrogenase transcripts. MC3T3-E1 cells were cultured as described above, and CFK2 cells were cultured in Roswell Park Memorial Institute (RPMI)-1640 media supplemented with 10% FCS and 10 mM HEPES. Total RNA was extracted by Trizol reagent (GIBCO BRL, Tokyo, Japan) from tibiae of D3-treated or normal mice and from treated or untreated MC3T3-E1 and CFK2 cells. Then, 5 μg of total RNA was reverse-transcribed using Superscript II (GIBCO BRL). PCR reactions (50 μl) contained 5 μl of 10x reaction buffer, 1 μl of 25 pmol of each primer, 1 μl of 10 mM of dNTPs mixture, 1 U of Taq polymerase, 3 μl of 25 mM MgCl₂, and 2 μl of reverse transcription (RT)-DNA and sterile distilled water. Amplification was performed according to Suda et al. (37), with denaturation of 94°C for 1 min, annealing at 55°C for 1 min, and extension at 72°C for 1 min, using a control system PC-700 (ASTEL, Tokyo, Japan). PCR transcripts were electrophoresed in a 1% agarose gel. A 454-bp fragment of mouse PTHR and a 415-bp fragment of mouse glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were amplified using primers reported by Suda et al. (37) and Tso et al. (38), respectively. For analysis of the effect of cycloheximide on D3-dependent inhibition, CFK2 and MC3T3-E1 cells were seeded in 10-cm dishes at 10^4 cells/cm² and cultured for 2 days. Cells were then washed once with PBS before addition of appropriate media and stripped serum. Cells were treated with 0.1% ethanol (vehicle), 100 nM D3, and/or 200 nM cycloheximide as indicated for 24 h before harvest of RNA. Note that when cells were treated with a combination of D3 with cycloheximide, the latter was added 1 h before D3 addition.

Western blotting. MC3T3-E1 and CFK2 cells were cultured and treated with D3 and/or cycloheximide as described above. As a positive control, COS-7 cells were cultured and transfected with a VDR expression vector as described (39). Cell pellets were resuspended in lysis buffer (50 mM Tris-HCl [pH 7.5], 1% NP40, 150 mM NaCl, 1 mM EDTA) containing one tablet per 10 ml of complete protease inhibitors (Boehringer Mannheim, Indianapolis, Indiana, USA), and incubated for 10 min on ice. Cell debris were collected by centrifugation, and 30 μg of each supernatant was loaded on a 10% SDS polyacrylamide gel. After electrophoresis, proteins were transferred to a Hybond C membrane (Amersham Life Sciences, Buckinghamshire, United Kingdom) and probed by Western analysis using an anti-VDR primary antibody MA1-710 (Affinity BioReagents, Golden, Colorado, USA) and an anti-rat anti-IgG secondary antibody (Boehringer Mannheim), each diluted 1:1,000. Blots were developed by chemiluminescence using the manufacturer’s protocol (Du Pont NEN Research Products, Boston, Massachusetts, USA).

Binding assay of 125I-labeled[Tyr34] human PTH(1-34) in MC3T3-E1 cells. MC3T3-E1 cells were cultured to 80% confluency in 24-well plates in α-MEM supplemented with 10% FCS. Cells were then incubated overnight using α-MEM without FCS. 125I-labeled[Tyr34] human PTH(1-34) (Amersham Life Sciences) was diluted with α-MEM plus 10% FCS to 10,000 cpm/100 μl. Cold human PTH (1-34) (10^{-6} to 10^{-11} M) was also prepared in

Figure 1
In situ hybridization demonstrating expression of P1- and P2-specific transcripts in bone and cartilage of mouse tibia. (a) Weak expression of the P1-specific probe (brown color) is observed in osteoblasts located on bony trabeculae below the epiphyseal growth plate (GP), and in chondrocytes in the proliferative zone and upper region of the hypertrophic zone of the growth plate. (b) Intense P2-specific expression (brown color) was detected in numerous osteoblasts (ob) lining bony spicules in the metaphysis, in chondrocytes in the proliferative zone, and in the upper region of the hypertrophic zone of the growth plate (GP). Control experiments using sense probe for P1-specific (c) and P2-specific (d) transcripts showing no hybridization signals. a and b, ×120; c and d, ×80. B, bone.
Downregulation of PTHR gene expression in vivo and in vitro by D3. Expression of the PTHR gene (a) was detected by RT-PCR as described in Methods. At 25 cycles of amplification, PCR products in control (−) MC3T3-E1 cells in tibiae were more abundant than those observed after D3 treatment (+). At 40 cycles of amplification, no differences were observed between the PTHR PCR products obtained from control and D3-treated cells. RT-PCR for GAPDH at 20 cycles revealed the same level of gene expression in both control and D3-treated MC3T3-E1 cells and mouse tibiae (b). Arrows in a and b denote the positions of the PCR products of the PTHR and GAPDH genes respectively. GAPDH, glyceraldehyde-3-phosphate dehydrogenase; PTHR, parathyroid hormone receptor; RT, reverse transcription.

Figure 2

α-MEM plus 10% FCS. Cells were briefly washed twice with α-MEM containing 10% FCS, and then incubated with either [125I]labeled PTH alone or a mixture of labeled and unlabeled PTH for 2 h at 36°C. Cells were then washed three times with cold PBS, and 1 ml of 1 N NaOH was added to each well to recover bound PTH. After 1 h of incubation, the NaOH solution was transferred to scintillation vials, and radioactivity was measured by scintillation counting.

In situ hybridization analysis of PTHR coding sequence and P1 and P2 promoter–specific transcripts. Probes complementary to P1- and P2-specific transcripts and PTHR coding sequence were generated as described (36). In brief, pU1/U2 was constructed by inserting a 220-bp cDNA fragment into Bluescript SK+ digested with XbaI and XhoI; pU3/170 was constructed by PCR amplification of 170 nucleotides of exon U3 from plasmid pU3A/X. The probes were digested with Apal and Xbal, and inserted into the corresponding sites of Bluescript SK+. Sense and antisense RNA probes for U1/U2 were obtained by in vitro transcription using T7 or T3 RNA polymerase of pU1/U2 digested with XhoI or Xbal, respectively, in the presence of digoxigenin-UTP (Boehringer Mannheim). Sense and antisense probes for U3 were obtained by in vitro transcription of pU3/170 with Apal or Xbal, respectively. In situ hybridization was performed using deparaffined sections on poly-L-lysine-coated glass slides treated with 10 μg/ml proteinase K and 0.2 N HCl. Hybridization of sections was performed by incubation for 10 min with 0.25% acetic anhydride in 0.1 M triethanolamine (pH 8.0). A hybridization mixture composed of 50% formamide, 10 mM Tris-HCl (pH 7.6), 100 μg/ml tRNA, 1× Denhardt’s solution, 10% dextran sulfate, 600mM NaCl, 0.25% SDS, and 1mM EDTA was used for hybridization at 50°C, including each cRNA probe at a concentration of 0.1–1.0 μg/ml. After hybridization, nonspecific binding of probes was reduced by RNase A treatment at 37°C for 30 min. Detection of signals was performed with antibody to digoxigenin, then made visible with nitroblue tetrazolium salt and 5-bromo-4-chloro-3-indolylphosphate.

Immunocytochemistry for the PTHR, and TNAPase and TRAPase enzyme histochemistry. Dewaxed-paraffin sections were pretreated with 1% BSA in PBS (1% BSA-PBS) for 30 min, followed by incubation overnight at 4°C with rabbit antisera 1K-XX1-89 against PTHR (15, 36) at a dilution of 1:200. Sections were then incubated with horseradish peroxidase (HRP)–conjugated goat anti–rabbit IgG (Calbiochem-Novabiochem Corp., San Diego, California, USA) at a dilution of 1:100 overnight at 4°C. For immunostaining of tissue nonspecific alkaline phosphatase (TNAPase), paraffin sections were incubated with rabbit serum to TNAPase (40) after pretreatment with 1% BSA-PBS for 30 min. Sections were then incubated with HRP-conjugated goat anti–rabbit IgG at a dilution of 1:100 overnight at 4°C. Sections were viewed using dianimobenzidine (DAB) substrate under light microscopic observation. For tartrate-resistant acid phosphatase (TRAPase) staining, specimens were rinsed with PBS and incubated in a mixture of 8 mg of naphthol AS-BI phosphate (Sigma Chemical Co., St-Louis, Missouri, USA), 70 mg of red violet LB salt (Sigma Chemical Co.), and 50 mM L(-)-tartaric acid (0.76 g; Nakalai Tesque, Kyoto, Japan) diluted in 0.1 M sodium acetate buffer (pH 5.0) for 15 min at 37°C. Sections were then counterstained with methyl green.

Quantitation of osteoclasts and preosteoclasts between control and D3-treated mice. Quantitative assessment of osteoclasts and pre-osteoclasts was performed by counting cells between 2.5 mm from the chondro-osseous junction and the diaphysis surrounding cortical bones on both sides. Histological sections (n = 15) of D3-treated and control animals were examined. Statis-
Methods for details.

Expression of PTHR gene and 5′-fluorescence in situ hybridization with an antisense probe recognizing P1-specific transcripts revealed only weak signals in both osteoblasts and chondrocytes (Fig. 1a). This is in contrast to the strong P1-specific signals detected in kidney (36). Conversely, the downstream promoter P2 is highly expressed both in growth plate chondrocytes and in osteoblasts lining the bony trabeculae (Fig. 1b). Activity was also detected in many cells in bone marrow, emphasizing that P2 is the predominant promoter in many cell types. Control experiments using sense probes for P1- and P2-specific transcripts did not show hybridization signals (Fig. 1, c and d). These data extend our previous RNase protection experiments, which suggested that P1 expression is mainly restricted to kidney, whereas P2 expression is widespread (35).

Cell-specific regulation of PTHR gene expression by D3. PTH and D3 are major hormones controlling extracellular fluid calcium concentrations, and interplay between the two hormones is complex. Previous work showed that D3 can downregulate PTH gene expression in the parathyroids (6, 7, 43). Given that bone is a major site of action of both PTH and D3, it was interesting to determine if D3 modulated the expression of PTHR in bone. We analyzed the effect of D3 on PTHR gene expression in situ and in vitro using RT-PCR analysis of PTHR transcripts from the mouse tibia and the mouse osteoblast-like cell line MC3T3-E1. Similar to mouse tibia, P2 is the predominant PTHR gene promoter in MC3T3-E1 cells (35). Total RNA isolated from mouse tibiae was subjected to reverse transcription and 25 cycles of amplification with coding sequence-specific primers, which gave rise to lower levels of PCR products from D3-treated animals than from untreated controls. Essentially identical results were obtained with RNA isolated from MC3T3-E1 cells treated with D3 in culture and untreated controls (Fig. 2a).

Expression of PTHR transcripts in D3-treated mouse tibia and MC3T3-E1 cells was seen after 40 cycles, which was beyond the linear range. RT-PCR analysis (20 cycles) of GAPDH RNA showed that D3 had no effect on GAPDH expression in either mouse tibia or in MC3T3-E1 cells treated with CHX, D3, or D3 and CHX in combination as indicated. Controls were run with 0.5 μg of internal control plasmid, and 5 μl of Lipofectamine (GIBCO BRL) were used according to the manufacturer’s instructions. Twenty-four hours after transfection, media was changed to α-MEM/10% stripped FCS and RPMI-1640/10 mM HEPES/10% stripped FCS for MC3T3-E1 and CFK2, respectively. Transfected cells were treated with 0.1% ethanol (vehicle) or 100 nM D3 for 24 h. Cells were then washed once with PBS and harvested with 200 μl of 1× Promega lysis buffer per 3.5-cm dish. Assays for β-galactosidase were as described (39). Luciferase assays were performed with 25 μl of cell lysates in 75×12-mm tubes (Sarstedt, Newton, North Carolina, USA). After lysates had reached room temperature, 75 μl of luciferase reagent (Promega Corp., Madison, Wisconsin, USA) was added to each tube. Activity was determined by EG&G Berthold Lumat LB 9506 luminometer (Bad Wildbad, Germany).

Figure 4
Downregulation of PTHR gene expression by D3 in MC3T3-E1 cells is not blocked by cycloheximide. (a) Expression of PTHR and GAPDH transcripts were analyzed by RT-PCR in untreated MC3T3-E1 cells (–), or in cells treated with CHX, D3, or D3 and CHX in combination as indicated. Controls were run with 0.5× volumes of RT reactions to demonstrate that amplifications were in the linear range. (b) RT-PCR analysis of RNA from CFK2 cells similar to that shown in a. PCR products were detected by Southern analysis using the internal sequences 5′-CAAGGAGCATG-GATTTCTTAACG-3′ for PTHR gene and 5′-AGGTGATCATGGA-CACTTGGT-3′ for GAPDH. (c) Control Western analysis of VDR expression levels in treated and untreated MC3T3-E1 and CFK2 cells. Extracts of transiently transfected COS-7 cells were used as a positive control for VDR expression. The position of the 50.5-kDa ovalbumin marker (Bio-Rad Laboratories Inc., Mississauga, Ontario, Canada) is indicated. See Methods for details. CHX, cycloheximide; VDR, D3 receptor.

tical analysis was performed by the Student’s t test. Preosteoclasts were identified as mononuclear cells positive for TRAPase staining, while osteoclasts were identified as TRAPase-positive cells possessing more than two nuclei.

Reporter plasmids and transient transfections. The promoter-less pXP2 has been described (41). The plasmid pP12.3 contains a 2.3 kb BamHI–PstI fragment of P1 inserted in the polylinker of pXP2. The plasmids pP21.6 and pP26.0 contain 1.6 kb and 6.0 kb HpaII–PvuII fragments, respectively, of the P2 promoter region inserted in the polylinker of pXP2. The β-galactosidase reporter plasmid VDRE3-lacZ contains three copies of the mouse osteopontin gene vitamin D3 response element derived from VDRE3x3CAT (39) placed upstream of a minimal promoter from the hsp68 gene. The β-galactosidase reporter p610AZ, used as an internal control with luciferase reporter plasmids, has been described (42). The plasmid pXP2-tk, which contains a truncated herpes simplex virus thymidine kinase promoter inserted in the polylinker of pXP2, was used as an internal control with VDRE3-lacZ. MC3T3-E1 cells were cultured as described above. Media was changed every 3 days. Cells were passaged before they reached confluence. Twenty-four hours before transfection, cells were seeded in 3.5-cm dishes at 10^5 cells per dish for MC3T3-E1 and 10^6 cells per dish for MC3T3-E1 and CFK2, respectively. For each transfection, 1.5 μg of reporter plasmid, 0.5 μg of internal control plasmid, and 5 μl of Lipofectamine (GIBCO BRL) were used according to the manufacturer’s instructions. Twenty-four hours after transfection, media was changed to α-MEM/10% stripped FCS and RPMI-1640/10 mM HEPES/10% stripped FCS for MC3T3-E1 and CFK2, respectively. Transfected cells were treated with 0.1% ethanol (vehicle) or 100 nM D3 for 24 h. Cells were then washed once with PBS and harvested with 200 μl of 1× Promega lysis buffer per 3.5-cm dish. Assays for β-galactosidase were as described (39). Luciferase assays were performed with 25 μl of cell lysates in 75×12-mm tubes (Sarstedt, Newton, North Carolina, USA). After lysates had reached room temperature, 75 μl of luciferase reagent (Promega Corp., Madison, Wisconsin, USA) was added to each tube. Activity was determined by EG&G Berthold Lumat LB 9506 luminometer (Bad Wildbad, Germany).
E1 cells (Fig. 2b). Therefore, expression of the PTHR gene was reduced by D3 both in vivo and in vitro. The regulation of PTHR by D3 at the protein level was examined by a competitive binding assay of PTH to MC3T3-E1 cells. The results (Fig. 3) show that D3 significantly reduced specific $^{125}$I-labeled PTH binding to MC3T3-E1 cells ($P < 0.05$).

The effect of cycloheximide treatment on D3-dependent inhibition of PTHR gene expression was examined in MC3T3-E1 cells. Treatment with cycloheximide alone for 24 hours had no effect on PTHR mRNA levels (Fig. 4a, and data not shown). As expected, reduced levels of PTHR mRNA were detected by RT-PCR in extracts of D3-treated cells. Moreover, the effect of D3 was not abolished by treatment with cycloheximide (Fig. 4a), indicating that D3 acts directly to inhibit PTHR gene expression. We also analyzed the effect of D3 on PTHR gene expression in the rat chondrocyte cell line CFK2 (44). In contrast to MC3T3-E1 cells, D3 did not effect PTHR mRNA levels in CFK2 cells (Fig. 4b, and data not shown). Western analyses demonstrated that the VDR expression in both MC3T3-E1 and CFK2 cells was not affected by treatment with D3 and cycloheximide, alone or in combination. These and further experiments (see below) confirmed that both cell lines express functional VDRs. The above in vitro experiments were extended to analyses of PTHR gene expression in mouse tibiae. The distribution of PTHR coding sequences detected in mouse tibiae by in situ hybridization was essentially identical to that of P2-specific sequences, i.e., in chondrocytes extending from the proliferative zone to the upper region of the hypertrophic zone of the growth plate, and in both preosteoblasts and osteoblasts below the growth plate (Fig. 5). This is consistent with our previous reports of in vivo binding of PTH and PTHrP to bone and cartilage cells (15, 45–47). D3 treatment markedly decreased the expression of the PTHR coding region in both preosteoblasts and osteoblasts. In contrast, growth plate chondrocytes still demonstrated intense expression of the PTHR (Fig. 5).

Immunohistochemistry was performed to examine the effects of D3 in vivo on PTHR protein levels in mouse tibiae (Fig. 6). PTHR immunoreactivity was observed in pre-osteoblasts and osteoblasts and in chondrocytes of the growth plate. After D3 treatment, immunoreactivity for
indicating stimulated osteoclastic activity (Fig. 7, c and d). There was penetration between the epiphysis and metaphysis of D3-treated tibiae, again reflecting enhanced bone resorption. Taken together, these results indicate that D3 downregulates PTHR gene expression in bone, but not in cartilage, under conditions where it enhances bone resorption.

**Effect of D3 on P2 promoter usage in bone and cartilage.** We next examined, by in situ hybridization, the regulation of expression of P2-specific transcripts in tibiae of control and D3-treated mice. In keeping with previous results, control mice displayed expression of P2-specific transcripts in both preosteoblasts and osteoblasts, and in chondrocytes in the proliferative zone and the upper hypertrophic zone of the growth plate (Fig. 8a) — a pattern similar to that seen with the PTHR coding region (Fig. 5a). However, reduced expression of P2-specific transcripts in osteoblasts and preosteoblasts, but not in chondrocytes of the growth plate, was observed in D3-treated tibiae (Fig. 8b), consistent with repression of PTHR gene transcription from the downstream promoter, P2, in osteoblasts, but not in chondrocytes.

**Inhibition of P2 promoter activity by D3 in MC3T3-E1 cells requires upstream sequences.** The inhibition of PTHR gene expression by D3 was further investigated in a series of gene-transfer experiments in MC3T3-E1 and CFK2 cells, performed with plasmid recombinants containing P1 or P2 promoter sequences fused to a luciferase reporter gene (Fig. 9a). Control experiments were performed with a synthetic D3-sensitive promoter fused to lacZ (Fig. 9a) to test for VDR function in these cells. Treatment with D3 stimulated lacZ expression to similar levels (three- to fourfold) in both cell lines (Fig. 9b). These results, coupled with the results of Western blotting (Fig. 4), demonstrate the presence of functional VDRs in MC3T3-E1 and CFK2 cells. No expression of luciferase activity above background was observed in either MC3T3-E1 or CFK2 cells transfected with P12.3-luc (Fig. 9, c and d, lanes 1–4), whereas activity was observed in either cell line transfected with P26.0-luc or P21.6-luc recombinants (Fig. 9, c and d, lanes 5–8). This is consistent with the relative activities of endogenous P1 and P2 promoters in these cells (ref. 35, and data not shown), and with the expression of P2-specific transcripts in bone and cartilage in vivo observed by in situ hybridization. Treatment of CFK2 cells with D3 had no effect on expression of luciferase activity from P1 or P2 (Fig. 9d). In contrast, D3 significantly downregulated luciferase activity expressed in MC3T3-E1 cells transfected with P26.0-luc (P < 0.05), but not in cells transfected with P21.6-luc (Fig. 9b, lanes 5–8), indicating that D3 represses transcription of the P2 promoter by acting on upstream promoter sequences. The standard deviations in these experiments were largely due to variations from one independent transfection to another in fold inductions of luciferase activities relative to the low activity of promoter-less control vectors. D3 treatment consistently reduced activity of P26.0-luc to an average of 66 ± 19% over four experiments. The magnitude of this effect is in excellent agreement with reduced binding of 125I-labeled PTH to D3-treated MC3T3-E1 cells (Fig. 3) and is similar to the degree of D3-dependent downregulation observed on other promoters (48, 49). Taken together,
metaphyseal osteoblasts and in chondrocytes of the growth plate (growth plate chondrocytes). Scripts in osteoblasts. Strong gene expression was still observed in the growth plate chondrocytes. In situ hybridization detecting gene expression of P2 promoter–specific transcripts in control and D3-treated mouse tibiae. (a) Control tibiae showed strong gene expression of P2-specific transcripts (brown color) in metaphyseal osteoblasts and in chondrocytes of the growth plate (GP). (b) D3-treated tibiae showed reduced expression of P2-specific transcripts in osteoblasts. Strong gene expression was still observed in the growth plate chondrocytes. ×120. B, bone.

Discussion
The active metabolite of vitamin D3 binds to the nuclear receptor VDR, which is expressed in both osteoblastic cells of bone (50–52) and in cartilaginous cells of the growth plate (53–55). Here we have confirmed that the PTHR is also expressed in osteoblastic cells of bone and in chondrocytes located mainly in the proliferative zone and the upper hypertrophic zone of the growth plate. We have also demonstrated that D3 acts in a cell-specific manner to downregulate the PTHR in osteoblasts, but not in chondrocytes. In bone, D3 enhances resorption and, along with PTH, stimulates the release of skeletal calcium and the maintenance of extracellular calcium homeostasis. In our studies, D3 produced a typical increase in osteoclasts numbers and activity that is responsible for accelerated resorption of bone. The effect of D3 has been ascribed to an augmented fusion of pre-osteoclasts to produce multinucleated differentiated osteoclasts (56–61). PTH, PTHrP, and D3 can increase osteoclasts to produce multinucleated differentiated osteoclasts (56, 57). PTH, PTHrP, and D3 can increase osteoclastic numbers and activity that is apparently through binding of each ligand to their cognate receptors in osteoclastic cells. This stimulates the release-soluble or cell-bound mediators (e.g., cytokines) that enhance preosteoclastic proliferation, differentiation, and/or fusion (62). The D3-induced downregulation of the PTHR in osteoblastic cells that we observed both in vitro and in vivo would be expected to reduce the effectiveness with which PTH or PTHR enhance osteoclastic activity. The inhibitory effect of D3 on the PTHR in osteoblasts in vivo was selective inasmuch as TNAPase activity was unaffected. Studies in the osteoblastic cell line ROS 17/2.8 have suggested that D3 downregulates the PTHR while increasing expression of osteocalcin (63). D3 is also known to suppress PTH and PTHrP production (48, 49, 64). Consequently, the downregulation by D3 of both the ligands and their osseous receptors may represent a homeostatic control mechanism designed to limit the bone resorptive and calcium-mobilizing activities that D3 manifests and to prevent excessive increases in extracellular calcium.

D3 is known to modulate proliferation and differentiation of chondrocytes in growth plates as well as to facilitate normal calcification in the cartilage matrix near the chondro-osseous junction (53, 55, 65). Severe D3 deficiency produces a dyschondroplastic phenotype (rickets) characterized by accelerated chondrocyte proliferation, retarded chondrocyte maturation, and diminished calcification. A very different phenotype results from PTHrP deficiency, which is characterized by diminished chondrocyte proliferation, altered maturation, and premature calcification (13–16). Consequently, although the coordinated action of PTHrP and D3 is necessary, their roles our results indicate that D3 acts to inhibit transcription of the predominant PTHR gene promoter P2 in osteoblasts, but not in chondrocytes, and that this action requires upstream promoter sequences.

Figure 9
Downregulation of P2 promoter activity in MC3T3-E1, but not in CFK2, cells. (a) Promoter reporter recombinants used in this study. (b) MC3T3-E1 or CFK2 cells were transiently transfected with VDRE3-lacZ and the tk-luc internal control plasmid, and cells were treated with 100 nM D3 as indicated. Activity of β-galactosidase was normalized to luciferase activity to correct for variations in transfection efficiency. D3 treatment gave rise to a significant increase in β-galactosidase expression in both MC3T3-E1 and CFK2 cells (n = 4; **P < 0.01). (c) MC3T3-E1 or CFK2 cells were transfected as indicated with luciferase reporter plasmids and p610AZ β-galactosidase expression as an internal control. Luciferase activities were normalized to β-galactosidase expression. Cells were treated with 100 nM D3 as indicated. Data are from three to five independent experiments, and standard deviations are indicated. D3 treatment caused a significant repression of luciferase expression in MC3T3-E1 cells transfected with pP26.0 (n = 4; * P < 0.05). Statistical analyses of paired values were performed using a two-tailed Student’s t test.
in the cartilaginous growth plate are distinct and not overlapping or redundant. The inability of D3 to reduce the efficacy of PTHrP in cartilage, as manifested by lack of downregulation of the PTHR, may therefore reflect the unique complementary roles these two factors subserve in the growth plate. The downstream PTHR promoter, P2, is clearly the major promoter employed in both bone and cartilage cells and is active in all cell types expressing the receptor (Figs. 1 and 8). Our in vitro studies demonstrated that high levels of luciferase reporter gene activity were expressed under the control of P2, but not P1, sequences in both MC3T3-E1 osteoblastic and C2K2 chondrocytic cell lines (Fig. 9). In contrast, our previous findings showed that P1 activity dominates and drives expression in all cell types expressing the PTHR in kidney, including glomerular podocytes, capillary endothelial cells, vascular smooth muscle, and tubular epithelial cells (36), whereas P2 activity is restricted to tubular epithelial cells. Consequently, the regulation of the renal and osseous expression of the PTHR gene is not tightly coordinated in the mouse.

Our in vitro studies have suggested that D3 reduces PTHR expression in osteoblasts, at least in part, by inhibiting transcription of the P2 promoter from sequences more than 1.6 kb upstream of the transcription initiation site. The magnitude of the inhibition observed (~35%) is similar to the effect of D3 on PTHrP gene transcription observed in gene-transfer experiments (48). The mechanism of D3-dependent transcriptional inhibition is not clear. Studies with the rat PTHrP gene have identified a negative vitamin D response element (VDRE) composed of directly repeated motifs separated by 3 bp that resemble elements found in genes upregulated by D3 (48). It was suggested that this element binds the VDR as a heterodimer with retinoid X receptors (RXRs) the same oligomeric combination that binds to upregulatory elements. VDR/RXR heterodimers may act to displace more powerful transactivators to repress, but not eliminate, PTHrP gene transcription. Unlike the PTHrP gene, the negative VDRE in the PTH gene is composed of only a single motif (43, 49). Interaction of the VDR expressed in bovine parathyroid extracts with the PTH gene element apparently does not require RXR (64), suggesting that the VDR may bind with a cell-specific negative regulatory factor. In contrast, the negative VDRE in the PTH gene was bound by VDR/RXR heterodimers expressed in rat osteoblast-like cells (64), suggesting that negative regulation of transcription by the VDR in osteoblasts may not occur by the same mechanism as in the parathyroid glands. Given these results and the findings in our study, it will now be possible to probe the molecular mechanisms controlling the cell-specific inhibition of PTHR gene expression by the VDR in osteoblastic models.

Acknowledgments
This work was supported in part by the Uehara Memorial Foundation (to N. Amizuka); the Foundation for Total Health Promotion (to N. Amizuka); Ministry of Education, Science and Culture of Japan Grants-in-Aid 08771562 (to N. Amizuka) and 0840756 (to H. Ozawa); Medical Research Council of Canada grants MT-12896 (to J.H. White) and MT-5775 (to D. Goltzman); and by a grant from the National Cancer Institute (to D. Goltzman). J.H. White is a chercheur-boursier of the Fonds de Recherche En Sante du Quebec. M.Y. Kwan is the recipient of a Medical Research Council of Canada Scholarship.